Clinical trial NCT02974348 - References

Drug Resistant Malaria Due to Plasmodium Falciparum — Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

Citation(s)

•   Ashley EA, White NJ
  Artemisinin-based combinations. Curr Opin Infect Dis. 2005 Dec;18(6):531-6. Review.
•   Basco LK, Same-Ekobo A, Ngane VF, Ndounga M, Metoh T, Ringwald P, Soula G
  Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull World Health Organ. 2002;80(7):538-45.
•   Brasseur P, Druilhe P, Kouamouo J, Brandicourt O, Danis M, Moyou SR
  High level of sensitivity to chloroquine of 72 Plasmodium falciparum isolates from southern Cameroon in January 1985. Am J Trop Med Hyg. 1986 Jul;35(4):711-6.
•   Breman JG, Alilio MS, Mills A
  Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):1-15. Review.
•   Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV
  A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001 Jan 25;344(4):257-63.
•   Mangham LJ, Cundill B, Achonduh OA, Ambebila JN, Lele AK, Metoh TN, Ndive SN, Ndong IC, Nguela RL, Nji AM, Orang-Ojong B, Wiseman V, Pamen-Ngako J, Mbacham WF
  Malaria prevalence and treatment of febrile patients at health facilities and medicine retailers in Cameroon. Trop Med Int Health. 2012 Mar;17(3):330-42. doi: 10.1111/j.1365-3156.2011.02918.x.
•   Mbacham W, Evehe M, Mbulli A, Akaragwe I, Tawe B, Djoko C, Gang B, Masumbe P, Mokube A, Atogho B, Ebeng R
  (2005b) Therapeutic efficacy of Sulfadoxine-Pyrimethamine (Fansidar®) and mutation rates to Anti-folate genes in different regions of Cameroon. Acta Trop, 95S:337.
•   Mbacham W
  F., Njuabe MT., Evehe MS., Moyou R., Skobo A., (2005a) Antimalarial drug studies in Cameroon reveal deteriorating fansidar and amodiaquine cure rates. Malaria research and control in Cameroon.. J. Cam. Acad. Sci., 5 : 58-63.
•   Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD
  Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012 Feb 4;379(9814):413-31. doi: 10.1016/S0140-6736(12)60034-8.
•   Mutabingwa TK
  Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Acta Trop. 2005 Sep;95(3):305-15. Review.
•   NMCP (2007)
  National Malaria Control Program malaria report 2007.
•   Ringwald P, Keundjian A, Same Ekobo A, Basco LK
  Chemoresistance of Plasmodium falciparum in the urban region of Yaounde, Cameroon. Part 2: Evaluation of the efficacy of amodiaquine and sulfadoxine-pyrimethamine combination in the treatment of uncomplicated Plasmodium falciparum malaria in Yaounde, Cameroon. Trop Med Int Health. 2000 Sep;5(9):620-7. French.
•   Silachamroon U, Krudsood S, Thanachartwet W, Tangpukdee N, Leowattana W, Chalermrut K, Srivilairit S, Wilaiaratana P, Thimasarn K, Looareesuwan S
  An open, randomized trial of three-day treatment with artesunate combined with a standard dose of mefloquine divided over either two or three days, for acute, uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health. 2005 May;36(3):591-6.
•   Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, Lindegardh N, Singtoroj T, Ashley E, Lwin S, Stepniewska K, White NJ
  Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet. 2006 Jun 24;367(9528):2075-85.
•   Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI
  The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005 Mar 10;434(7030):214-7.
•   Soula G
  , Ndounga M., Foumane V., Olivier G., Youmba J.C. Basco L. K., Boudin C., Same Ekobo A.., Ringwald P. (2000). Bilan de la résistance de P. falciparum à la chloroquine au Cameroun et alternatives thérapeutiques. Bull.liais. doc. OCEAC : 33(4) : 13-22.
•   Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, Rosenthal PJ
  Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet. 2001 Aug 4;358(9279):368-74.
•   Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, Dong TH, Tran TT, Stepniewska K, White NJ, Farrar J
  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet. 2004 Jan 3;363(9402):18-22.
•   Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A, Wongsrichanalai C
  In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health. 2006 Feb;11(2):211-9.
•   Whegang SY, Tahar R, Foumane VN, Soula G, Gwét H, Thalabard JC, Basco LK
  Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon. Malar J. 2010 Feb 19;9:56. doi: 10.1186/1475-2875-9-56.
•   World Health Organization
  Guidelines for the treatment of malaria. 1st ed. Geneva: WHO, 2006.
•   World malaria Report (2011)
  Global malaria incidence and Mortality rates
•   Zikusooka CM, McIntyre D, Barnes KI
  Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests? Malar J. 2008 Sep 15;7:176. doi: 10.1186/1475-2875-7-176.

Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

Details for clinical trial NCT02974348